Core Viewpoint - GSK has received FDA approval to expand the age range for its RSV vaccine, Arexvy, to include adults aged 18 to 49 at increased risk of lower respiratory tract disease, enhancing its market potential [1]. Company Summary - GSK's Arexvy is already approved for adults aged 60 and above, as well as at-risk adults aged 50 to 59 [1]. - The vaccine targets a significant population, with an estimated 21 million adults under 50 in the U.S. having at least one risk factor for severe RSV infection [1]. - Arexvy will compete with Moderna's mRESVIA and Pfizer's Abrysvo in the 18-49 age group [1]. Industry Summary - RSV is a common respiratory virus that leads to seasonal infections and is a major cause of pneumonia and death in infants and older adults [1]. - The European Medicines Agency has also supported the use of Arexvy for all adults above the age of 18, indicating a broader acceptance and potential market expansion in Europe [1].

Core Viewpoint - Moderna Inc. has resolved a four-year legal dispute regarding patent infringement related to its lipid nanoparticle (LNP) delivery technology, resulting in a significant stock price increase of 15.99% to $57.80 [1]. Group 1: Legal Settlement Details - Moderna has agreed to pay a total of $2.5 billion to Arbutus Biopharma Corporation and Genevant Sciences GmbH to settle the LNP patent infringement case, with $950 million to be paid as a lump sum in Q3 and the remaining $1.3 billion contingent on the outcome of its appeal [2]. - The legal issue involved allegations that Moderna used Arbutus and Genevant's LNP technology for its Spikevax and mRESVIA vaccines without permission [4]. - If Moderna prevails in its appeal, no further payments will be required; however, if liability is affirmed, an additional payment of up to $1.3 billion will be due within 90 days of the decision [5]. Group 2: Financial Implications - Moderna expects to record charges of $950 million in the first quarter related to the settlement and anticipates ending the year with cash and cash equivalents between $4.5 billion and $5 billion [6].

Core Viewpoint - Moderna Inc. has reached a settlement agreement worth $950 million with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine, Spikevax, and its mRESVIA product [2][3]. Financial Implications - The settlement will involve a lump sum payment of $950 million in Q3, with potential additional payments of up to $1.3 billion depending on the outcome of a legal appeal regarding government-contractor immunity [2][3]. - If the additional payment is realized, it would represent the largest disclosed patent settlement in the pharmaceutical industry and the second largest in any industry [3]. Future Outlook - CEO Stéphane Bancel stated that resolving this litigation allows the company to focus on its near-term future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and cash equivalents [3][4]. - The company anticipates returning to revenue growth in 2026 and aims for a strong balance sheet with over $5 billion in liquidity by that time, targeting breakeven in 2028 [4]. Analyst Perspectives - Following the settlement, Moderna shares have increased, as the settlement value was better than anticipated. Analysts had previously considered the potential liability to be close to $5 billion [5][6]. - Analyst Myles Minter noted that the resolution of litigation provides certainty regarding funding for multiple late-stage oncology readouts expected in 2026 [6]. Legal Context - The lawsuit alleged that Moderna's mNEXSPIKE relied on proprietary technology developed and patented by BioNTech [7]. Earnings Performance - Moderna reported a fourth-quarter loss of $2.11, which was better than the expected loss of $2.59, and lower than a loss of $2.91 a year ago. Quarterly sales reached $678 million, exceeding expectations of $626.097 million [8]. Stock Performance - The stock is currently trading 4.5% above its 20-day simple moving average (SMA) and 5.2% above its 100-day SMA, indicating short-term strength [9]. - Over the past 12 months, shares have significantly increased and are closer to their 52-week highs, reflecting a positive long-term trend. The stock carries a Hold rating with an average price target of $34.40 [10]. Recent Analyst Actions - Recent analyst ratings include Piper Sandler with an Overweight rating and a target of $69.00, Goldman Sachs with a Neutral rating and a target of $41.00, and RBC Capital with a Sector Perform rating and a target of $30.00 [11].

Financial Data and Key Metrics Changes - In 2025, the company reported revenues of $1.9 billion, primarily driven by sales of the COVID vaccine Spikevax and mNEXSPIKE [4][10] - Operating expenses decreased by $2.2 billion, or 30% year-over-year, reflecting significant cost management efforts [4] - The net loss for the year was $2.8 billion, an improvement from a net loss of $3.6 billion in 2024 [14] - Cash and investments at the end of 2025 totaled $8.1 billion, down from $9.5 billion at the end of 2024 [14][15] Business Line Data and Key Metrics Changes - The company had three products on the market in 2025: Spikevax, mNEXSPIKE, and mRESVIA, with mNEXSPIKE becoming the leading product in the U.S. shortly after its launch [7] - Total revenue for the fourth quarter was $700 million, with $300 million from the U.S. and $400 million from international markets [10] - U.S. revenue for the full year was $1.2 billion, while international revenue was $700 million [10] Market Data and Key Metrics Changes - In the U.S., despite a decline in overall COVID market demand, the company maintained strong market share in the retail channel, particularly with mNEXSPIKE [11] - Internationally, the company achieved revenue at the higher end of expectations, driven by operational performance and vaccination rates [11] Company Strategy and Development Direction - The company aims for up to 10% revenue growth in 2026, primarily from international markets and local manufacturing in the U.K. and Australia [15][16] - Strategic partnerships in Latin America and Asia Pacific are expected to drive growth, alongside the anticipated launch of multiple vaccines in Europe by 2027 [20][22] - The company is focused on expanding its oncology pipeline and expects significant clinical milestones in 2026 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the FDA's refusal to file letter regarding the flu program, highlighting challenges in the regulatory environment [5] - The company remains optimistic about its growth potential, citing strong momentum heading into 2026 with multiple levers for revenue growth [19][33] - Management emphasized the importance of cost discipline and the adoption of AI tools to improve productivity [33] Other Important Information - The company announced a five-year strategic agreement with the government of Mexico for respiratory vaccine supply [7] - A new Chief Development Officer, Dr. David Berman, was appointed to enhance the oncology pipeline [9] Q&A Session Summary Question: Implications of flu RTF on cash flow break-even guidance and INT program timing - Management noted that the flu filing is under review in Europe, Canada, and Australia, with the U.S. refile pending a Type A meeting with the FDA [37] - The INT program for adjuvant melanoma is event-driven, with data expected this year [41] Question: Thoughts on flu and COVID combination vaccine refile - The company is awaiting feedback from the FDA on what is needed to refile the mRNA-1010 program [45] - The phase III study for mRNA-1010 showed superior efficacy compared to standard vaccines [46] Question: European COVID vaccination market and flu vaccine strain selection - The company anticipates a larger market share in Europe, with mNEXSPIKE expected to be competitive [54] - Discussions on better strain matching for flu vaccines are ongoing, with strong support from international regulators [57]

Financial Data and Key Metrics Changes - In 2025, the company reported revenues of $1.9 billion, primarily driven by sales of its COVID vaccine Spikevax and mNEXSPIKE [4][10] - Operating expenses decreased by $2.2 billion, or 30% year-over-year, reflecting significant cost management efforts [4] - The net loss for the year was $2.8 billion, an improvement from a net loss of $3.6 billion in 2024 [14] - Cash and investments at year-end totaled $8.1 billion, down from $9.5 billion at the end of 2024 [14][15] Business Line Data and Key Metrics Changes - The company had three products on the market in 2025: Spikevax, mNEXSPIKE, and mRESVIA, with mNEXSPIKE quickly becoming the leading product in the U.S. [7] - Total revenue for the fourth quarter was $700 million, with $300 million from the U.S. and $400 million from international markets [10] - The U.S. revenue for the full year was $1.2 billion, while international revenue was $700 million [10] Market Data and Key Metrics Changes - In the U.S., despite a decline in overall COVID market demand, the company maintained strong market share in the retail channel, particularly with mNEXSPIKE capturing 24% of the total U.S. retail market [11][25] - Internationally, revenue performance was driven by operational efficiency and vaccination rates meeting expectations [10] Company Strategy and Development Direction - The company aims for up to 10% revenue growth in 2026, primarily from international markets and local manufacturing in the U.K. and Australia [15][16] - Strategic partnerships in Latin America and Asia Pacific are expected to drive growth, alongside the anticipated launch of multiple vaccines in 2027 [20][22] - The company is focused on expanding its oncology pipeline and expects significant clinical milestones in 2026 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the FDA's refusal to file letter regarding the flu program, highlighting regulatory uncertainty as a challenge for innovation [5] - The company remains optimistic about its growth trajectory, citing strong momentum and multiple levers for revenue growth [19][33] Other Important Information - The company has completed enrollment in several late-stage oncology studies and anticipates data readouts in 2026 [28][32] - A new Chief Development Officer has joined the company, expected to enhance the oncology pipeline [9] Q&A Session Summary Question: Implications of flu RTF on cash flow break-even guidance and INT program timing - Management is pleased with the flu filing progress in Europe and Canada, with the U.S. refile dependent on the Type A meeting with the FDA [36] - The INT program for adjuvant melanoma is event-driven, with data expected this year [40] Question: Thoughts on flu and COVID combination vaccine re-filing - The company is awaiting feedback from the FDA on what is needed for re-filing the mRNA-1010 program [43] - The phase III study for mRNA-1010 showed superior efficacy compared to standard vaccines [45] Question: European COVID vaccination market and flu vaccine strain selection - The company anticipates a larger market than the current $700 million estimate, with mNEXSPIKE expected to capture significant share [52] - Discussions on better strain matching for flu vaccines are ongoing, with strong support from international regulators [55][57] Question: Higher-than-expected cash balance explanation - The cash balance exceeded expectations due to lower cash costs and strong working capital performance [60] Question: Details on the adjuvant phase 3 melanoma study and Norovirus confidence - The adjuvant melanoma study includes interim analyses, with the first expected this year [65] - The Norovirus vaccine is targeting older adults, with a different approach than previous studies [68]

Financial Data and Key Metrics Changes - In 2025, the company reported revenues of $1.9 billion, primarily driven by sales of its COVID vaccine Spikevax and mNEXSPIKE [5][11] - Operating expenses decreased by $2.2 billion, or 30%, compared to the previous year [5] - The net loss for the year was $2.8 billion, an improvement from a net loss of $3.6 billion in 2024 [14] - The company ended the year with $8.1 billion in cash and investments, down from $9.5 billion at the end of 2024 [14][15] Business Line Data and Key Metrics Changes - The company had three products on the market in 2025: Spikevax, mNEXSPIKE, and mRESVIA, with mNEXSPIKE quickly becoming the leading product in the U.S. [7] - For the fourth quarter, total revenue was $700 million, with $300 million from the U.S. and $400 million from international markets [11] - The U.S. revenue totaled $1.2 billion for the full year, while international revenue was $700 million [11] Market Data and Key Metrics Changes - In the U.S., despite a decline in overall COVID market demand, the company maintained strong market share in the retail channel, supported by the successful launch of mNEXSPIKE [12] - Internationally, operational performance and vaccination rates exceeded expectations, contributing to revenue growth [11] Company Strategy and Development Direction - The company aims for total revenue growth of up to 10% in 2026, primarily driven by international markets and local manufacturing agreements in the U.K. and Australia [15][16] - The company plans to launch mNEXSPIKE and its combination flu-COVID vaccine in Europe by the 2027 winter season, expanding its market share [20][21] - Strategic partnerships in Latin America and Asia Pacific are expected to drive growth, alongside the anticipated approval of its flu vaccine in multiple countries [21][27] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the FDA's refusal to file letter regarding the flu program, highlighting the challenges posed by regulatory uncertainty [6] - The company remains optimistic about its pipeline and expects continued clinical momentum, particularly in oncology and infectious disease programs [32][33] Other Important Information - The company has completed enrollment in several late-stage cancer studies and anticipates data readouts in 2026 [9][28] - A new Chief Development Officer, Dr. David Berman, will join the company, bringing extensive experience in clinical-stage immunotherapies [10] Q&A Session Summary Question: Implications of flu RTF on cash flow break-even guidance and INT program timing - Management noted that the flu filing is under review in Europe, Canada, and Australia, with the U.S. refile pending a Type A meeting with the FDA [36][37] - The INT program for adjuvant melanoma is event-driven, with data expected this year [42] Question: Thoughts on flu and COVID combination vaccine refile - The company is awaiting feedback from the FDA on what is needed to refile the mRNA-1010 program, with a comprehensive data set already submitted [45][47] - The phase III study for mRNA-1010 showed superior efficacy compared to standard vaccines [49][50] Question: European COVID vaccination market and flu vaccine strain selection - The company anticipates a larger market share in Europe, with mNEXSPIKE expected to be competitive [56][58] - Discussions on better strain matching for flu vaccines are ongoing, with strong support from international regulators [59][61]

Core Insights - Moderna (MRNA.US) has several key events to watch in 2026, including financial performance, vaccine approvals, and clinical data releases Financial Performance - The company plans to release its Q4 and full-year 2025 financial report on February 13, 2026 [2] Project Advancements - In the seasonal vaccine sector, the independent flu vaccine mRNA-1010 is expected to receive regulatory approval in multiple regions in 2026 [3] - The RSV vaccine mRESVIA is anticipated to have Phase III clinical trial data available in 2026 [3] Product Development Progress - In oncology, the personalized cancer vaccine mRNA-4157, developed in collaboration with Merck, may announce Phase III clinical trial data in 2026 [4] - The company's independently developed cancer vaccine mRNA-4359 is expected to have potential Phase II clinical data released in 2026 [4] - Ongoing Phase II/III clinical trials for indications such as non-small cell lung cancer will continue [4] Rare Disease Initiatives - The therapy mRNA-3927 for propionic acidemia has achieved target enrollment for its registration study, with data expected in 2026 [5] - The clinical Phase III study for the norovirus vaccine mRNA-1403 will undergo interim analysis in 2026 [5]

Core Insights - Moderna's mRESVIA vaccine generated $2 million in sales and is approved for adults aged 60 and older in 40 countries, with additional approval for high-risk adults aged 18 to 59 in 31 countries [1] - Total revenue for the third quarter was reported at $1 billion, primarily driven by COVID vaccine sales of $971 million, including $781 million in the U.S. and $190 million internationally [2] - The company anticipates full-year U.S. revenue between $1 billion and $1.3 billion, reflecting ongoing volatility in vaccination trends [5] Financial Performance - Total product sales reached $973 million, with additional revenue of $43 million from collaborations and grants [2] - Moderna reported a net loss of $200 million due to decreased revenue, despite ending the quarter with $6.6 billion in cash and investments [5] - Analysts expect a GAAP loss of $2.60 per share for Q4, with revenue projected to fall by 37% to $623.9 million [8] Pipeline and Future Growth - Moderna has three approved products, with two programs reporting positive Phase 3 results and five additional candidates in clinical studies [6] - The company is developing a seasonal flu vaccine candidate, mRNA-1010, and a flu-plus-COVID combination vaccine, mRNA-1083, with regulatory filings expected before January 2026 [6] - Moderna is also expanding into oncology and rare diseases, with multiple late-stage studies underway in partnership with Merck [7] Market Position and Analyst Ratings - MRNA stock has risen 40% year-to-date but is down 25% from its 52-week high of $55.20 [3] - Analysts rate MRNA stock as a consensus "Hold," with two analysts rating it as a "Strong Buy" and one as a "Moderate Sell" [10] - The average target price for MRNA shares is $37.35, with a high price estimate suggesting potential upside of 228% over the next 12 months [10]

Core Viewpoint - Moderna has faced challenges in maintaining revenue growth from its coronavirus vaccine but has shown a strong start in 2026 with a 58% increase in stock price, raising questions about a potential sustained bull run for the company [1]. Group 1: Recent Developments - Moderna's recent data from a five-year follow-up study on intismeran autogene, in combination with Merck's Keytruda, demonstrated a 49% reduction in disease recurrence or death for advanced melanoma patients compared to Keytruda alone [3]. - Intismeran autogene is currently in a phase 3 study and is being investigated across multiple cancer types, with a total of eight phase 2 or phase 3 studies ongoing [4]. Group 2: Market Position and Opportunities - Moderna has established itself as a leader in mRNA-based therapies and the coronavirus vaccine market, with recent clinical progress and the launch of mRESVIA, a vaccine for respiratory syncytial virus [5]. - The partnership with Merck for intismeran autogene presents a significant commercial opportunity, potentially leading to blockbuster status, despite profit-sharing with Merck [6]. Group 3: Future Prospects - Moderna is expected to make sustained clinical and regulatory progress with several candidates in mid or late-stage clinical trials, which could diversify its lineup of approved products in the next three years [7].

Core Insights - Merck is set to report its Q4 and full-year 2025 results on February 3, with a focus on the sales performance of its cancer drug Keytruda, which accounted for over 50% of pharmaceutical sales in the first nine months of 2025 [2][11] - Keytruda's sales increased by 8% year over year in Q3 2025, but were below expectations, prompting attention on Merck's non-oncology drugs, particularly Capvaxive and Winrevair, which are expected to drive long-term growth [3][5] Sales Performance - Keytruda's sales performance is critical, with a noted increase of 8% year over year in Q3 2025, but weaker than anticipated [3] - Capvaxive and Winrevair have shown strong sales, with Capvaxive generating $480 million and Winrevair $976 million in the first nine months of 2025 [5][11] - The Animal Health business is also contributing to top-line growth, with expected revenue increases in Q4 [6] Product Approvals and Market Competition - Capvaxive was approved in the U.S. in June 2024 and in the EU in March 2025, while Winrevair was approved for PAH treatment in 2024 [4] - Enflonsia, a new RSV antibody, recorded sales of $79 million in Q3 2025, with its performance in Q4 still uncertain as it moves into broader clinical use [7] - Winrevair faces competition in the PAH market from United Therapeutics and Johnson & Johnson, while Enflonsia competes with AstraZeneca/Sanofi's Beyfortus [8][10] Financial Performance and Valuation - Merck's shares have increased by 30.6% over the past six months, outperforming the industry and the S&P 500 [13] - The company's price/earnings ratio stands at 15.61, which is lower than the industry average of 18.36 but higher than its 5-year mean of 12.48 [14] - The Zacks Consensus Estimate for 2025 earnings per share has slightly decreased from $8.98 to $8.95, and for 2026 from $8.81 to $6.94 over the past 60 days [15]